Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy
Authors:
- Kimihiko YukisadaKYKimihiko Yukisada
- Antonio SibuloASAntonio Sibulo
- Kudsia HafeezKHKudsia Hafeez
- Yan JiaYJYan Jia
- Jack ZhangJZJack Zhang
- 1 April 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 35 (4) , 877-885
Abstract
The objective of this study is to evaluate the efficacy and safety of sacubitril/valsartan (LCZ696, an angiotensin receptor and neprilysin inhibitor) add-on to amlodipine compared with amlodipine monotherapy in Asian patients with systolic hypertension uncontrolled with amlodipine. Patients with mean clinic SBP at least 145 mmHg and less than 180 mmHg after a 4-week treatment with amlodipine 5 mg/day were randomized to receive LCZ696/amlodipine (200/5 mg/day) or amlodipine 5 mg/day for 8 weeks. The primary assessment was the superiority of LCZ696/amlodipine versus amlodipine in lowering 24-h ambulatory SBP from baseline to week 8. Secondary assessments included 24-h ambulatory DBP and pulse pressure (PP), daytime and night-time BP, clinic BP and PP, BP control/responder rate (<140/90 mmHg or a reduction ≥20/10 mmHg from baseline), and safety. Of the 371 patients screened, 266 (71.7%) patients (mean age 55.4 years; 24-h SBP/DBP 139.0/86.1 mmHg at baseline) who did not respond to 4-week treatment with amlodipine 5 mg/day were randomized. At week 8, LCZ696/amlodipine provided greater reductions in 24-h SBP compared with amlodipine monotherapy from baseline (-13.9 versus -0.8 mmHg, P < 0.001). All the secondary efficacy assessments were significantly (P < 0.001) in favour of LCZ696/amlodipine, for instance, 24-h PP (-5.8 versus -0.6 mmHg). Overall, the incidence of adverse events was 20.0% with LCZ696/amlodipine and 21.3% with amlodipine. LCZ696/amlodipine showed significantly greater 24-h ambulatory BP and PP reductions compared with amlodipine monotherapy. Both treatments were generally well tolerated. Therefore, LCZ696/amlodipine combination could be an effective treatment for patients with systolic hypertension uncontrolled with amlodipine.Keywords
This publication has 33 references indexed in Scilit:
- Challenges in the management of hypertension in AsiaEuropean Heart Journal Supplements, 2012
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyThe Lancet, 2010
- Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapyCurrent Medical Research and Opinion, 2009
- Four Blood Pressure Indexes and the Risk of Stroke and Myocardial Infarction in Japanese Men and WomenCirculation, 2009
- Molecular Biology of the Natriuretic Peptide SystemHypertension, 2007
- Blood Pressure Control in Patients with Hypertension: a Community-Based StudyClinical and Experimental Hypertension, 2006
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Blood Pressure Indices and Cardiovascular Disease in the Asia Pacific RegionHypertension, 2003
- Pulse PressureHypertension, 1997